Concepedia

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

Filippo Montemurro, Antonio Antón, Rachel Wuerstlein, Suzette Delaloge, Jacques Bonneterre, Nathalie Quénel-Tueux, Sabine C. Linn, Natsumi Irahara, Margarita Donica, Nicolas Lindegger,

European Journal of Cancer · 2019 · 102 citations · 11 references

DOIFull text

Open access

Concepts

References

11

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

, , +14

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

, , +12

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1.6K citations · Full text

, , +17

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology · 2014 · 716 citations

, , +16

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology · 2017 · 523 citations

, , +17